Compare Remitly Global Inc (RELY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs Sana Biotechnology Inc — how do they compare? Remitly Global Inc trades at $23.77 (market cap $4.98B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Remitly Global Inc is far larger — about 6× Sana Biotechnology Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and Sana Biotechnology Inc for 23 Days on average.
| RELY | SANA | |
|---|---|---|
Market Cap | $4.98B | $836.71M |
Volume | 3,501,150 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $26.92 | $5.92 |
52-Week Low | $12.20 | $2.68 |
Typical Hold Time | 53 Days | 23 Days |
Enterprise Value | $4.34B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.675, up 3.25% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats. Revenue surged to $1.64 billion in 2025, with net income turning positive at $67.93 million, reflecting a significant improvement in profitability. Recent news highlights partnerships, such as with Etsy, and strong analyst consensus favoring the stock.
The outlook for RELY is positive, driven by robust revenue growth, expanding margins, and a favorable analyst consensus with a $30.50 price target. Key risks include competitive pressures in fintech and reliance on sustained customer acquisition, but institutional interest and insider holdings suggest confidence in long-term value.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
